<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109312</url>
  </required_header>
  <id_info>
    <org_study_id>HTX-011-401</org_study_id>
    <nct_id>NCT05109312</nct_id>
  </id_info>
  <brief_title>A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE</brief_title>
  <official_title>A Phase 4, Randomized, Blinded, Active-Controlled Study of HTX-011 in Subjects Undergoing Different Surgical Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate&#xD;
      HTX-011 compared with bupivacaine HCl in subjects undergoing different surgical procedures.&#xD;
      Each parallel cohort will enroll subjects undergoing a unique surgical procedure: total&#xD;
      shoulder arthroplasty (TSA) in Cohort 1 and abdominoplasty in Cohort 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In each cohort, subjects will be randomized in a 2:1 ratio to HTX-011 or bupivacaine HCl, respectively. All subjects will receive a scheduled postoperative non opioid multimodal analgesic (MMA) regimen.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs).</measure>
    <time_frame>Through Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of bupivacaine and meloxicam</measure>
    <time_frame>Through 144 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of occurrence of maximum concentration (Tmax) of bupivacaine and meloxicam</measure>
    <time_frame>Through 144 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from Time 0 to the time of the last quantifiable concentration (AUClast) of bupivacaine and meloxicam</measure>
    <time_frame>Through 144 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf) of bupivacaine and meloxicam</measure>
    <time_frame>Through 144 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t½) of bupivacaine and meloxicam</measure>
    <time_frame>Through 144 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-011 + multimodal analgesic (MMA) regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2 Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl + MMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-011 + MMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2 Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl + MMA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>100 mg</description>
    <arm_group_label>Treatment Group 2 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>125 mg</description>
    <arm_group_label>Treatment Group 2 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <description>400 mg</description>
    <arm_group_label>Treatment Group 1 Cohort 1</arm_group_label>
    <arm_group_label>Treatment Group 1 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Luer lock applicator</intervention_name>
    <description>Applicator for instillation</description>
    <arm_group_label>Treatment Group 1 Cohort 1</arm_group_label>
    <arm_group_label>Treatment Group 1 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>400 mg</description>
    <arm_group_label>Treatment Group 1 Cohort 1</arm_group_label>
    <arm_group_label>Treatment Group 1 Cohort 2</arm_group_label>
    <arm_group_label>Treatment Group 2 Cohort 1</arm_group_label>
    <arm_group_label>Treatment Group 2 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>1 g</description>
    <arm_group_label>Treatment Group 1 Cohort 1</arm_group_label>
    <arm_group_label>Treatment Group 1 Cohort 2</arm_group_label>
    <arm_group_label>Treatment Group 2 Cohort 1</arm_group_label>
    <arm_group_label>Treatment Group 2 Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.&#xD;
&#xD;
          -  Is scheduled to undergo a unilateral Total Shoulder Arthroplasty (TSA) or&#xD;
             abdominoplasty.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is undergoing a revision surgery.&#xD;
&#xD;
          -  Has a known or suspected history of hypersensitivity or clinically significant&#xD;
             idiosyncratic reaction to bupivacaine (or other local anesthetics), NSAIDs,&#xD;
             acetaminophen, oxycodone, morphine, or hydromorphone.&#xD;
&#xD;
          -  History of severe allergic reaction to aspirin or other NSAIDs, or known history of&#xD;
             severe gastrointestinal adverse reactions associated with NSAID use&#xD;
&#xD;
          -  Has taken meloxicam within 10 days prior to the scheduled surgery, or any NSAID within&#xD;
             24 hours prior to the scheduled surgery, with the exception of subjects on low-dose&#xD;
             (≤100 mg) daily acetylsalicylic acid for cardioprotection&#xD;
&#xD;
          -  Opioid use for most days within the last 3 months prior to Screening in the opinion of&#xD;
             the Investigator.&#xD;
&#xD;
          -  Has been administered immediate-release bupivacaine HCl within 5 days prior to the&#xD;
             scheduled surgery, or a modified-release bupivacaine product within 14 days prior to&#xD;
             the scheduled surgery.&#xD;
&#xD;
          -  Has initiated treatment with any of the following medications within 1 month prior to&#xD;
             study drug administration: selective serotonin reuptake inhibitors, selective&#xD;
             norepinephrine reuptake inhibitors, gabapentin, pregabalin, duloxetine, or&#xD;
             cyclooxygenase-2 inhibitors.&#xD;
&#xD;
          -  Has been administered systemic steroids within 5 half-lives or 10 days prior to the&#xD;
             scheduled surgery (whichever is longer).&#xD;
&#xD;
          -  Has a known or suspected history of drug abuse, a positive drug screen (except for&#xD;
             cannabinoids) on the day of surgery, or a history of alcohol abuse within the past 5&#xD;
             years.&#xD;
&#xD;
          -  Suspected or confirmed active coronavirus disease 2019 (COVID-19) infection&#xD;
&#xD;
          -  Had a malignancy in the last year, with the exception of nonmetastatic basal cell or&#xD;
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Has undergone 3 or more surgeries within 12 months, other than for diagnostic&#xD;
             procedures (eg, colonoscopy).&#xD;
&#xD;
          -  Has a body mass index (BMI) &gt;40 kg/m2.&#xD;
&#xD;
          -  Had undergone prior abdominoplasty or major abdominal wall surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie Visonneau</last_name>
    <phone>858-251-7232</phone>
    <email>svisonneau@herontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Woodland International Research Group, LLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>total shoulder arthroplasty</keyword>
  <keyword>abdominoplasty</keyword>
  <keyword>multimodal analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

